Morning Research on Amgen, Affymax, Vertex Pharma, Questcor Pharma, and Repros Therapeutics

The healthcare sector is undergoing a major transformation after the Supreme Court last year upheld President Obama's Affordable Care Act (ACA). While supporters of ACA say that the reform will benefit the healthcare industry in the long-term,critics say that reform will hurt research and development as it will result in higher costs for the industry. For biotechnology companies such as Amgen Inc. (NASDAQ: AMGN),Affymax Inc. (NASDAQ: AFFY),Vertex Pharmaceuticals Inc. (NASDAQ: VRTX),Questcor Pharmaceuticals Inc. (NASDAQ: QCOR),and Repros Therapeutics Inc. (NASDAQ: RPRX),the key will be to keep their costs under control as they adapt to the new operating environment. Biotechnology stocks ended mostly higher in Thursday's trading session tracking gains in the broad market. StockCall has posted free technical research reports on AMGN,AFFY,VRTX,QCOR,and RPRX and these can be accessed by signing up at

[ http://www.stockcall.com/analysis ]

Amgen Inc. shares rose sharply on Thursday, touching a 52-week high. The stock rose to a 52-week high of $102.62 before paring some of the gains to finish the day 2.36% higher at $102.51 on above average volume of 5.51 million. Amgen's shares gained nearly 6% in the last three sessions. The stock gained more than 19% in the first quarter, outperforming the broad market. The company's shares have seen a series of highs over the past two weeks, which is a strong bullish signal. Download the free report on AMGN upon registration at

[ http://www.StockCall.com/AMGN040113.pdf ]

Shares of Affymax Inc. rallied in trading on Thursday. The stock rose to an intra-day high of $1.42 before finishing the day 10.89% higher at $1.38 on volume of 5.99 million. Despite Thursday's gains, Affymax's shares are down more than 92% in 2013 so far. The stock is trading more than 95% below its 52-week high of $27.74. The company's shares are also trading significantly below their 50-day and 200-day moving averages. AFFY technical report can be accessed for free by signing up at

[ http://www.StockCall.com/AFFY040113.pdf ]

Vertex Pharmaceuticals Incorporated edged higher in trading on Thursday; however, the gains were limited. The stock closed 0.26% higher at $54.97 on above average volume of 2.36 million. The biotech company's shares gained more than 2.30% last week. For the first quarter, the stock rose more than 31%, compared to a gain of over 10% for the S&P 500. Its shares are now trading close to $56 resistance level. The free report on VRTX can be downloaded by signing up now at

[ http://www.StockCall.com/VRTX040113.pdf ]

Shares of Questcor Pharmaceuticals Inc. edged higher in last Thursday's trading session. The stock closed 0.34% higher at $32.54 on volume of 1.15 million. Questcor's shares have gained nearly 22% so far this year, easily outperforming the broad market. The stock is currently trading above its 50-day moving average and slightly below its 200-day moving average. Free report on QCOR can be accessed by registering at

[ http://www.StockCall.com/QCOR040113.pdf ]

Repros Therapeutics Inc.'s shares saw a huge rally in trading on Thursday after the company said that its testosterone treatment was successful in late-stage study. Repros shares rose to an intra-day high of $16.39 last Thursday before paring some of its gains to finish the day 76.34% higher at $16.10 on above average volume of 10.05 million. The biotech company's shares crossed above their 50-day and 200-day moving averages as a result of the rally in the previous week's last day of trading. Register with StockCall and download the research on RPRX for free at

[ http://www.StockCall.com/RPRX040113.pdf ]

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

[ http://www.stockcall.com ]

SOURCE StockCall.com

N@N

Morning Research on Amgen, Affymax, Vertex Pharma, Questcor Pharma, and Repros Therapeutics